Patents by Inventor Mark Willingham

Mark Willingham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230010020
    Abstract: A system and method for managing usage rights, and autonomous creation of a usage rights and release agreement between a client and a talent for usage rights of job materials. The system includes an interface module for generating a client interface and a talent interface; a negotiation module for generating usage rights charge based on the price, the details of the client, and the details of the job; a contract module to generate a usage rights and release agreement based on the details of a talent, the usage rights charge, the details of the client, and the details of the job to; and generating a contract between the client and a talent based on the usage rights and release agreement.
    Type: Application
    Filed: May 2, 2022
    Publication date: January 12, 2023
    Inventor: Mark Willingham
  • Publication number: 20100300804
    Abstract: The di-electric harness for fall arrest systems includes a full body harness having first and second webbings extending through a chest plate and back plate. The first and second webbings cross at the chest plate and at the back plate and form a loop at the back plate in which is disposed a D-ring. The first and second webbings each extend through a hip plate to form a leg strap. The chest plate, back plate and hip plates are made of non-metal.
    Type: Application
    Filed: May 26, 2010
    Publication date: December 2, 2010
    Applicant: WEB DEVICES, LLC
    Inventor: Mark Willingham
  • Publication number: 20080089875
    Abstract: A method of treating cancer comprises: (a) providing allogenic or autologous white blood cells from a suitable donor; and then (b) administering the white blood cells to the subject in an amount effective to treat the cancer. Preferably the white blood cells comprise innate immune cells. Preferably the white blood cells comprise less than 10% by number of cytotoxic T lymphocytes. Preferably the white blood cells, or more particularly the innate immune cells, are preselected in vitro to kill cancer cells in vitro (for example, by collecting white blood cells from the patient and determining that the white blood cells kill cancer cells in vitro before and thereby pre-selecting the donor, before collecting a subsequent population of cells from the donor for administration).
    Type: Application
    Filed: October 11, 2007
    Publication date: April 17, 2008
    Inventors: Zheng Cui, Mark Willingham
  • Publication number: 20070113298
    Abstract: We have established and studied a colony of mice with a unique trait of host resistance to both ascites and solid cancers induced by transplantable cells. One dramatic manifestation of this trait is age-dependent spontaneous regression of advanced cancers. This powerful resistance segregates as a single-locus dominant trait, is independent of tumor burden and is effective against cell lines from multiple types of cancer. During spontaneous regression or immediately following exposure, cancer cells provoke a massive infiltration of host leukocytes which form aggregates and rosettes with tumor cells. The cytolytic destruction of cancer cells by innate leukocytes is rapid and specific without apparent damage to normal cells. The mice are healthy, cancer-free and have a normal life span. These observations suggest a previously unrecognized mechanism of immune surveillance that may have potential for therapy or prevention of cancer.
    Type: Application
    Filed: October 25, 2006
    Publication date: May 17, 2007
    Inventors: Zheng Cui, Mark Willingham
  • Publication number: 20050022258
    Abstract: We have established and studied a colony of mice with a unique trait of host resistance to both ascites and solid cancers induced by transplantable cells. One dramatic manifestation of this trait is age-dependent spontaneous regression of advanced cancers. This powerful resistance segregates as a single-locus dominant trait, is independent of tumor burden and is effective against cell lines from multiple types of cancer. During spontaneous regression or immediately following exposure, cancer cells provoke a massive infiltration of host leukocytes which form aggregates and rosettes with tumor cells. The cytolytic destruction of cancer cells by innate leukocytes is rapid and specific without apparent damage to normal cells. The mice are healthy, cancer-free and have a normal life span. These observations suggest a previously unrecognized mechanism of immune surveillance that may have potential for therapy or prevention of cancer.
    Type: Application
    Filed: April 19, 2004
    Publication date: January 27, 2005
    Inventors: Zheng Cui, Mark Willingham
  • Patent number: 5990296
    Abstract: This invention provides for recombinant single chain antibodies capable of specifically binding to a Lewis.sup.Y -related carbohydrate antigen and fusion proteins comprising these antibodies. More particularly, the invention provides for single chain Fv regions of the monoclonal antibody B3. The invention also provides for a method of improving the binding affinity of antibodies lacking a serine at position 95 of the V.sub.H region that involves mutating position 95 to a serine.
    Type: Grant
    Filed: December 3, 1996
    Date of Patent: November 23, 1999
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ira Pastan, Mark Willingham, David Fitzgerald, Ulrich Brinkmann, Lee Pai
  • Patent number: 5608039
    Abstract: This invention provides for recombinant single chain antibodies capable of specifically binding to a Lewis.sup.Y -related carbohydrate antigen and fusion proteins comprising these antibodies. More particularly, the invention provides for single chain Fv regions of the monoclonal antibody B3. The invention also provides for a method of improving the binding affinity of antibodies lacking a serine at position 95 of the V.sub.H region that involves mutating position 95 to a serine.
    Type: Grant
    Filed: October 28, 1994
    Date of Patent: March 4, 1997
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Ira Pastan, Mark Willingham, David Fitzgerald, Ulrich Brinkmann, Lee Pai
  • Patent number: 4806494
    Abstract: Monoclonal antibodies are produced which specifically bind to human ovarian cancer cells. These antibodies are conjugated to Pseudomonas exotoxin in order to produce an immunotoxin suitable for the chemotherapeutic treatment of human ovarian cancer.
    Type: Grant
    Filed: July 24, 1986
    Date of Patent: February 21, 1989
    Assignee: The United States of America as represented by the Department of Health & Human Services
    Inventors: Ira Pastan, David J. Fitzgerald, Mark Willingham